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Molecular Pathways: Emergence of Protein
Kinase CK2 (CSNK2) as a Potential Target to
Inhibit Survival and DNA Damage Response
and Repair Pathways in Cancer Cells
Adam J. Rabalski1, Laszlo Gyenis1, and David W. Litchfield1,2
Abstract
Protein kinase CK2 (designated CSNK2) is a constitutively
active protein kinase with a vast repertoire of putative sub-
strates that has been implicated in several human cancers,
including cancer of the breast, lung, colon, and prostate, as
well as hematologic malignancies. On the basis of these
observations, CSNK2 has emerged as a candidate for targeted
therapy, with two CSNK2 inhibitors in ongoing clinical trials.
CX-4945 is a bioavailable small-molecule ATP-competitive
inhibitor targeting its active site, and CIGB-300 is a cell-per-
meable cyclic peptide that prevents phosphorylation of the E7
protein of HPV16 by CSNK2. In preclinical models, either of
these inhibitors exhibit antitumor efficacy. Furthermore, in
combinations with chemotherapeutics such as cisplatin or
gemcitabine, either CX-4945 or CIGB-300 promote synergistic
induction of apoptosis. While CSNK2 is a regulatory partici-
pant in many processes related to cancer, its potential to
modulate caspase action may be particularly pertinent to its
emergence as a therapeutic target. Because the substrate rec-
ognition motifs for CSNK2 and caspases are remarkably sim-
ilar, CSNK2 can block the cleavage of many caspase substrates
through the phosphorylation of sites adjacent to cleavage sites.
Phosphoproteomic strategies have also revealed previously
underappreciated roles for CSNK2 in the phosphorylation of
several key constituents of DNA damage and DNA repair
pathways. Going forward, applications of proteomic strategies
to interrogate responses to CSNK2 inhibitors are expected to
reveal signatures for CSNK2 inhibition and molecular insights
to guide new strategies to interfere with its potential to inhibit
caspase action or enhance the susceptibility of cancer cells to
DNA damage. Clin Cancer Res; 22(12); 2840–7. 2016 AACR.
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Background
Protein kinase CK2 (designated CSNK2) represents one small
protein kinase family that has recently emerged as a potential
therapeutic target based on alterations in its expressionor activity in
a number of cancers (Fig. 1; ref. 1). CSNK2 is composed of
two closely related catalytic isoforms (CSNK2A1 or CSNK2A2)
that both display catalytic activity in the presence or absence of its
regulatory CSNK2B; subunit (see Supplementary Table S1 for
definitions of the acronyms that appear throughout this article).
The regulatory CSNK2B subunit is not essential for activity but can
affect the ability of the catalytic subunits to phosphorylate certain
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substrates (2). A recent analysis of transcript expression profiles
for CSNK2A1, CSNK2A2, and CSNK2B in neoplastic tissues versus
normal tissues deposited in the Oncomine database revealed
varying degrees of altered expression of individual CSNK2 sub-
units, suggesting that deregulation of CSNK2 subunit expression
profiles promotes cancer (3). To this point, the CSNK2-dependent
phosphoproteome has not yet been fully elucidated, and the
impact of alterations in CSNK2 on the phosphoproteome has not
yet been systematically investigated. Nevertheless, it is evident both
from an extensive body of literature and computational predictions
of its substrates based on its consensus recognition motif (S/T-X-X-
D/E/pS/pY) that CSNK2 is involved in a vast landscape of biolog-
ical processes (Fig. 1), with more than 2,000 putative phosphor-
ylation sites in the human proteome (4). While more comprehen-
sive discussions of CSNK2 can be found elsewhere (5, 6), we high-
light the involvement of CSNK2 in specific cellular processes,
including its convergence with caspase pathways and its roles in
DNA response and repair pathways, which have inspired ongoing
efforts to exploit CSNK2 as a therapeutic target.
Convergence of CSNK2 with caspase pathways
CSNK2 is generally considered to be a constitutively active
enzyme (i.e., its catalytic subunits do not require activating
phosphorylation, association with its regulatory subunit, or
the presence of second messengers to be catalytically active),
which is expressed at higher levels in many forms of human
cancer (1, 3, 7, 8). CSNK2 has also been shown to be essential
for viability and to enhance cancer cell survival associated
with inhibition of apoptosis. These observations are partic-
ularly intriguing when considering the remarkable resem-
blance of the consensus recognition motif of CSNK2 with
that of caspases (Fig. 2A) that cleave substrates at aspartic
acid residues during the progression of apoptosis. In fact,
several published examples (Fig. 2A) show that caspase sub-
strates, including Bid, which promotes apoptotic progression
when it is cleaved, can be phosphorylated by CSNK2 at sites
adjacent to caspase cleavage sites. Because phosphorylation
adjacent to caspase cleavage sites blocks cleavage, these
observations suggest that increased phosphorylation by
CSNK2 could promote cell survival by inhibiting caspase
action (9–14).
Building on these observations, a combined computational
and biochemical approach revealed an extensive repertoire of
proteins with overlapping CSNK2 and caspase recognition
motifs suggesting that CSNK2 could have widespread impact
on caspase action (15). In addition to the identification of
many proteins known to be caspase substrates, these studies
also demonstrated that CSNK2 could phosphorylate CASP3













































































































CSNK2 has been implicated in a diverse
array of biologic processes. This figure
illustrates a selection of the biological
processes in which CSNK2 has been
implicated with examples of putative
substrates or interacting proteins
involved in each of these processes.
These proteins were identified and
analyzed using the following databases:
GO: biological processes according to
UniProt (52), Reactome (53), PHOSIDA
(54), and PubMed (55).
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Protein kinase CSNK2 plays pivotal
roles in the control of cell survival and
responses to DNA damage. A, on the
basis of the remarkable similarity of
the consensus recognition motifs for
phosphorylation by CSNK2 (S/T-D-X-
X-D/E) and cleavage by caspases (E-
X-D), it is evident that there are many
cellular proteins where CSNK2
phosphorylation could occur adjacent
to caspase cleavage sites toblock their
cleavage by caspases (15). As
described in the text, the proteins
shown here represent caspase
substrates including Bid, which
promotes apoptotic progressionwhen
it is cleaved, and CASP3, where CSNK2
phosphorylation adjacent to a caspase
cleavage site has been demonstrated
to block its activation (9, 10, 12–15). B,
proteins shown here are involved in
DNA damage repair, which requires
phosphorylation by CSNK2 to execute
respective DNA repair processes. A
recurring theme with the illustrated
proteins (i.e., MDC1, RAD51, and
TCOF1) is the ability of CSNK2 to
promote phosphorylation-dependent
interactions with the FHA domain of
the NBN component of the MRN
complex (21–24, 27). As described in
the text, the potential of CSNK2 to
block caspase action in the manner
shown in A has inspired efforts to use
CSNK2 inhibitors to render cancer cells
more susceptible to apoptosis.
Similarly, the involvement of CSNK2 in
DNA damage responses shown in B
has motivated the evaluation of
CSNK2 inhibitors for enhancing the
vulnerability of cancer cells to DNA-
damaging agents. DSB, double-
stranded break.
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to prevent its cleavage by upstream caspases activated by
intrinsic and extrinsic apoptotic stimuli (Fig. 2A). Collective-
ly, these findings demonstrate that CSNK2 has the potential
to inhibit caspase action at both the level of caspase activa-
tion and cleavage of downstream substrates. Furthermore,
these findings raise the prospect that the higher (i.e., path-
ologic) levels of CSNK2 that are observed in cancer cells
could result in the pathologic rewiring of caspase pathways
to promote cell survival. Interestingly, further character-
ization of the relationship between CSNK2 and caspases
revealed intriguing isoform specificity. In this respect, CASP3
appears to be preferentially phosphorylated by CSNK2A2
rather than CSNK2A1, despite the fact that these two iso-
forms of CSNK2 have very similar enzymatic characteristics
(16). Furthermore, CSNK2B attenuated phosphorylation,
suggesting that misregulation of CSNK2 subunits in cells
could be an additional mechanism to affect the regulation
of apoptosis (12). The capacity of CSNK2 to promote cancer
cell survival in vitro was also revealed in a recent large-scale
screen via RNA interference knockdown and cDNA overex-
pression of kinases in DLD-1 colorectal adenocarcinoma
cells in which overexpression of CSNK2A1 promoted resis-
tance to TNFSF10 as determined by flow cytometry using
antibodies against cleaved PARP and cleaved CASP3 (17).
Overall, while CSNK2 is only one of many constituents that
intersect caspase pathways, its ability to modulate caspase
action through phosphorylation of caspase substrates (poten-
tially including caspases themselves) represents one possible
mechanism by which CSNK2 might be exploited to neutral-
ize cancer cell survival.
CSNK2 and DNA damage response and repair pathways
Another manner in which CSNK2 may contribute to the
regulation of cancer cell survival that might be exploited for
intervention is through its involvement in DNA damage
response (DDR) and DNA repair pathways (Fig. 2B). In this
respect, recent large-scale phosphoproteomic analyses of G361
melanoma cells and GM00130 B lymphocyte cells treated
with the radiomimetic drug neocarzinostatin or with ionizing
radiation to induce DNA double-stranded breaks (DSB),
respectively, demonstrated a dynamic response in motifs pref-
erential for CSNK2 phosphorylation in many proteins. These
results reveal a previously underappreciated role for CSNK2
as an important mediator in the cellular response to DSBs
(18, 19). Other indications that CSNK2 is involved in DDR
and DNA repair pathways include the demonstration that
CSNK2A1 localizes to perinuclear structures whereas CSNK2A2
becomes nuclear in response to DSBs caused by ionizing
radiation (20). Some of the CSNK2 substrates that are involved
in DDR are scaffold proteins such as mediator of DNA damage
checkpoint 1 (MDC1), where phosphorylation of serine–aspar-
tate–threonine repeats regulates retention of the MRE11A–
RAD50–NBN (MRN) complex at DSBs through interactions
with Forkhead-associated (FHA) domains in the NBN compo-
nent of the MRN complex (21, 22). Another critical interaction
for NBN is colocalization to the nucleolus that is dependent on
the phosphorylation of TCOF1 by CSNK2 at threonine 210,
independent of MRE11A (23, 24). In terms of regulating
processes tasked with repairing damaged DNA, the phosphor-
ylation of XRCC1 by CSNK2 is required for single-strand break
repair (25), and phosphorylation of XRCC4 is necessary for
nonhomologous end joining repair (26). In homologous
recombination, phosphorylation of RAD51 by PLK1 at serine
14 primes the phosphorylation of threonine 13 by CSNK2,
regulating binding to the NBN component of the MRN complex
and facilitating recruitment of RAD51 to damaged DNA (27).
In another recent study, it was determined that the phosphor-
ylation of a deubiquitylase OTUB1 by CSNK2 is necessary for
its nuclear accumulation to promote the formation of TP53BP1
repair foci at DSBs (28). While undoubtedly many details
regarding its roles in DDR and DNA repair pathways remain
to be elucidated, these examples show that CSNK2 has an
important role in several discrete aspects of these processes.
A recurring theme that is highlighted by these examples is that
phosphorylation by CSNK2 promotes phosphorylation-depen-
dent interactions such as those involving the FHA domain of
the NBN component of the MRN complex. Overall, the wide-
spread involvement in these processes could be relevant to the
development of strategies that neutralize the advantages or
exploit the unique vulnerabilities of cancer cells.
Clinical–Translational Advances
As CSNK2 is implicated in a number of fundamental bio-
logical processes and found at varying levels of deregulation in
human cancers, widespread interest has been expressed in
targeting this kinase therapeutically (1). While there are many
inhibitors described in the literature (29), our discussion
focuses on two molecules, CX-4945 and CIGB-300, that have
advanced to clinical trials.
CX-4945: An ATP-competitive CSNK2 inhibitor in
clinical trials
CX-4945 was developed by Cylene Pharmaceuticals, Inc. and
is a potent and selective ATP-competitive inhibitor (Ki ¼ 0.38
nmol/L for CSNK2A1 and CSNK2A2 with an IC50 of 1 nmol/L)
with no extensive inhibitory activity against a panel of 238
kinases (30, 31). Characterization of its in vitro effects revealed
varying degrees of activation of caspase-3 and caspase-7 in
cancer cells with no detectable change of caspase-3/7 activity
in normal cells. Interestingly, CX-4945 elicited differential
effects on the cell cycle with BT-474 breast cancer cells arresting
in G2–M transition and BxPC-3 prostate cancer cells arresting in
G1 (31). In vitro studies employing CX-4945 in combination
with gemcitabine or cisplatin revealed enhanced antiprolifera-
tive effects in A2780 and SKOV-3 ovarian cancer cells. Anti-
proliferative activity was 23% to 38% higher than Bliss addi-
tivity when CX-4945 was added to cells after treatment with
gemcitabine or cisplatin. These treatments were also accompa-
nied by decreased phosphorylation of the CSNK2 substrates
XRCC1 and MDC1 and accumulation of single-stranded and
double-stranded DNA breaks (32). These data are in agreement
with the observations of CSNK2 localizing to the nucleus in
response to DSBs and for the role of CSNK2 in the DDR and
DNA repair mechanisms (20, 25, 33, 34). Currently CX-4945 is
in phase I/II clinical trials in the United States, South Korea, and
Taiwan for the treatment of cholangiocarcinoma in combina-
tion with gemcitabine and cisplatin (NCT02128282). The aim
of this trial is to determine its maximum tolerable dose in
patients followed by a randomized phase II assessment using
CX-4945 in combination with gemcitabine and cisplatin versus
the standard of care.
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CIGB-300: A CSNK2 inhibitory peptide in clinical trials
An alternative strategy for targeting CSNK2 emerged from a
screen performed with a phage display library to identify cyclic
peptides that bind to a peptide encoding amino acids 28-38 of the
E7 protein of human papillomavirus 16 (HPV16). This screen
yielded a cyclic peptide (termed P15) that blocked phosphory-
lation of recombinant HPV-16 E7 protein in vitro (35). When
fused to a cell-permeable peptide derived from the HIV-Tat
protein, the resulting peptide, designated CIGB-300, induced
caspase activation in TC-1 cells. Further characterization of
CIGB-300 was performed in human trials to investigate safety
and tolerability in female patients with cervical cancer, which
resulted in 75% of all patients in all treatment groups having
reduced total lesion areas, with 90% having partial response and
19.4% showing complete response in total lesion area reduction
(36). CIGB-300 also displays efficacy in vitro in chronic lympho-
cytic leukemia cell (CLL) lines (includingMEC1,WaC3D5, JVM3,
andMO1043), producing IC50 values between 27 and 38 mmol/L
with 72-hour treatment at 30 mmol/L resulting in less than 40%
cell viability (37). Antitumor activity of CIGB-300 in mouse
xenograft models of transplanted with MO1043 cells was also
effective, as mean tumor volume decreased more than 50%
relative to control treatment. (37). Other in vitro investigations,
using combinations of CIGB-300 with chemotherapeutic agents
including paclitaxel, doxorubicin, cisplatin, and 5-fluorouracil in
lung and cervical cancer cell models, show promise for further
clinical investigation (38). Paclitaxel displayed the strongest
synergism with CIGB-300 in NCI-H125 and SiHa cell lines, with
5-fold less peptide being required to achieve an antiproliferative
effect level of 94% inNCI-H125 cells.With the same combination
setting, the concentration of paclitaxel could be reduced more
than 3,000-fold without compromising the final antiproliferative
effect (38). Ongoing trials for optimization of CIGB-300 treat-
ment and delivery approaches highlight its utility as an alternative
to small-molecule ATP-competitive inhibitors for targeting
CSNK2 in cancer (39).
Emerging prospects for combinatorial treatments involving
CSNK2 inhibition
CX-4945 has been used in combination with other agents and
has shown promise for targeting a number of malignancies. For
example, CX-4945 has been studied in vitro in combination with
DNA-damaging agents in acute myeloid leukemia cell lines and
patient-derived cells (40). In another study of hematologicmalig-
nancies, CX-4945 showed a significant decrease in cell viability of
patient-derived CLL cell lines in vitro (41). When CX-4945 was
combinedwithGS-1101 (PI3KD inhibitor), ibrutinib (BTK inhib-
itor), or fludarabine, synergistic responses were observed in CLL
cell lines that were not observed in the unpaired treatments with
combination indices (using the Chou–Talalay method) of 0.46,
0.56, and 0.30 for CX-4945 and GS-1101, ibrutinib and fludar-
abine, respectively. Combinations of CX-4945 and bortezomib in
in vitro assays using patient-derived cells frommultiple myeloma
and mantle cell lymphoma also enhanced mitochondria-depen-
dent apoptosis associated with suppression of NFKB1 and STAT3
target genes leading to 50% reduction of NOS2 and BCL2 gene
expression (42). In other in vitro cell models of cancer such as
A431 epidermal carcinoma cells and H2170 lung cancer cells,
combining erlotinib and CX-4945 resulted in suppression of
AKT1 phosphorylation in addition to downregulation of phos-
phorylation sites on AKT1 andMTOR substrates (43). Combined
treatment resulted in a 3-fold increase in apoptosis as determined
by caspase-3 and caspase-7 activity assays in comparison with
treatment with CX-4945 or erlotinib alone. This enhanced anti-
proliferative effect was also demonstrated in mouse xenograft
models, with the greatest reduction in tumor volume resulting
from combined treatment in both A431 and H2170 xenograft
mice (43).
Because resistance is commonly observed with both chemo-
therapy and targeted therapy involving kinase inhibitors, inhibi-
tion of CSNK2has also been explored as a strategy for overcoming
both de novo resistance and acquired resistance. Analysis of several
multidrug-resistant cell lines revealed that CX-4945 sensitized
cells to vinblastine and doxorubicin, resulting in reduction of cell
viability by 50% when treating with vinblastine and a 2-fold
increase in doxorubicin accumulation in resistant cells (44). These
results indicate that CSNK2 inhibition may have utility for over-
coming de novo resistance.
There is also mounting evidence to suggest that CSNK2
inhibition may be effective to combat adaptive resistance.
Investigation of imatinib-resistant chronic myeloid leukemia
(CML) cell lines revealed 2-fold higher protein and activity
levels of CSNK2, along with increased localization of CSNK2A1
and CSNK2B to the cytoplasm of imatinib-resistant cells in
comparison with imatinib-sensitive cells (45). Interestingly,
treatment with CX-4945 abrogated CSNK2A1 and BCR-ABL1
interaction as determined by co-immunoprecipitation and glyc-
erol gradient sedimentation leading to the induction of apo-
ptosis in resistant cell lines at concentrations that failed to
promote PARP cleavage in imatinib-sensitive CML. Further-
more, treatment of imatinib-resistant CML cells with CX-
4945 or siRNA targeting CSNK2A1 promoted higher sensitivity
to lower concentrations of imatinib, suggesting that the kinome
had adapted in response to Bcr-Abl inhibition by imatinib,
leading to increased dependence on CSNK2 activity (45). In an
in vitro cell model of T-cell acute lymphoblastic leukemia, CX-
4945 downregulated the unfolded protein response as deter-
mined by HSPA5 expression and caused increased ERN1, phos-
phorylated EIF2S1, and DDIT3, indicating endoplasmic retic-
ulum stress. When paired with thapsigargin or temsirolimus the
synergistic cytotoxicity was further potentiated in these cell-
based assays (46). More recently, analysis of acquired resistance
in triple-negative breast cancer using SUM149 and SUM159 cell
lines in vitro revealed that resistance to the BET bromodomain
inhibitor JQ1 was associated with increased binding of BRD4 to
MED1 in a bromodomain-independent manner and dependent
on BRD4 phosphorylation by CSNK2A1, which keeps transcrip-
tional regulation of genes promoting cellular proliferation
active (47). The use of CSNK2 inhibitor or protein phosphatase
PPP2CA activators such as perphenazine decreased phosphor-
ylation of BRD4, suggesting a rationale for this combination for
tackling BET bromodomain inhibitor resistance in triple-nega-
tive breast cancer. Collectively, these observations raise the
prospect that CSNK2 inhibitors could be used to enhance the
effectiveness of other interventions.
Emerging considerations: Phosphoproteomic and kinome
profiling and characterization of signaling pathway "rewiring"
after small-molecule inhibition
With recent advances in mass spectrometry–based proteomics
and the increased sophistication of computational approaches, it
is now possible to explore cellular responses to kinase inhibition
Rabalski et al.
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on a proteome-wide scale. In addition to identification of direct
targets of individual kinases within cells, phosphoproteomic
studies are also revealing new relationships between different
kinases or kinase-mediated pathways within the complex and
intricate regulatory networks that orchestrate cellular processes.
For example, in a thyroid cancer cell line harboring the BRAF
V600E mutation, phosphoproteomic analysis following short-
term treatment (15 or 30 minutes) with vemurafenib (PLX4032)
or the MAP2K1/2 inhibitor selumetinib (AZD6244) revealed
increased phosphorylation of numerous sites. Interestingly,
approximately 50% of the upregulated sites conformed to the
CSNK2 consensusmotif, suggesting that CSNK2activity is affected
by inhibition of MAPK signaling (48). Building on that observa-
tion, combination of CX-4945 with vemurafenib demonstrated a
synergistic effect in reducing cell viability by60% inV600Emutant
thyroid cancer cells and inmutantmelanoma cell lines. In another
global phosphoproteomic study, CSNK2 phosphorylation sites
had increased phosphorylation site stoichiometry in gefitinib-
resistant PC9 lung cancer cells in comparison with gefitinib-
sensitive cells, in addition to having higher phosphorylation
stoichiometry than MAPK- or EGFR-regulated phosphorylation
sites (49). Collectively, results from these large-scale phospho-
proteomics studies imply that CSNK2may have an important role
in drug resistance mechanisms and offer new insights regarding
pathways that may be regulated or influenced by CSNK2.
As a companion to phosphoproteomic workflows, comple-
mentary proteomic strategies have been devised to monitor
kinome responses (e.g., simultaneously profiling the activity of
hundreds of kinases) when cells are treated with kinase inhibitors
(50). For example, multiplexed inhibitor beads (designated
MIBs) have been used as a means to capture and infer the activity
of hundreds of active kinases (i.e., the active kinome) from cell
extracts. With triple-negative breast cancer cells and mouse mod-
els, this approach revealed activation of receptor tyrosine kinases
such as PDGRFB and DDR1 in response to the MAP2K inhibitors
selumetinib or trametinib, which in turn activated downstream
kinases capable of activating the MAPK pathway through an
alternative route to circumvent inhibition (51). Based on these
observations, it is evident that the combined application of
proteomic and phosphoproteome strategies will reveal how cells
respond to specific drugs leading to insights regarding compen-
satory changes that contribute to resistance to kinase inhibitors
and the promise of combinations that might be devised to
effectively attenuate both primary and compensatory pathways.
In this respect, applications of proteomic and phosphoproteomic
strategies for profiling CSNK2 inhibitors would undoubtedly be
invaluable in assessing the prospect of resistance to CSNK2
inhibition and revealing the relationships of CSNK2 with other
constituents of the regulatory kinase networks.
Conclusions and Future Perspectives
At this stage, our understanding of how CSNK2 contributes
to malignancy remains far from complete. Nevertheless, based
on its capacity to interfere with caspase action to promote cell
survival, it can be envisaged that CSNK2 inhibitors could
neutralize the survival advantage of cancer cells. In a similar
respect, as CSNK2 is also involved in the DDR and DNA repair
pathways, it is anticipated that inhibition of CSNK2 could
enhance the vulnerability of cancer cells to interventions that
target these processes. To this point, two distinct CSNK2 inhi-
bitors, namely CX-4945 and CIGB-300, have advanced to
clinical trials. However, judging from the published literature,
patent databases, and abstracts from meetings such as the
Annual Meeting of the American Association for Cancer Re-
search, it is apparent that many additional CSNK2 inhibitors
may be on the horizon (29). It is also pertinent to consider how
the emergence of systematic proteomic and phosphoproteomic
workflows promise to guide clinical applications of CSNK2
inhibitors by revealing prognostic signatures for the identifi-
cation of malignancies that may be suitable for CSNK2-targeted
intervention, biomarkers for monitoring inhibitor action, and
adaptive responses that are elicited in response to CSNK2
inhibitors. Overall, despite concerns that its ubiquitous expres-
sion and widespread roles in biological processes would render
CSNK2 unsuitable as a target for intervention, a striking num-
ber of preclinical studies as well as initial reports from clinical
trials show very promising results. Looking to the future, it can
be imagined that CSNK2 inhibitors could be an important
addition to the arsenal of targeted agents that are exploited to
neutralize the advantages of cancer cells, deployed to enhance
their vulnerabilities, or used in combinations with other drugs
to overcome or anticipate resistance that continues to limit the
utility of many current therapeutic regimens.
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